Cargando…
Differential clinical profile of candesartan compared to other angiotensin receptor blockers
The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers rep...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2011
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253768/ https://www.ncbi.nlm.nih.gov/pubmed/22241949 http://dx.doi.org/10.2147/VHRM.S22591 |
_version_ | 1782220770384019456 |
---|---|
author | Cernes, Relu Mashavi, Margarita Zimlichman, Reuven |
author_facet | Cernes, Relu Mashavi, Margarita Zimlichman, Reuven |
author_sort | Cernes, Relu |
collection | PubMed |
description | The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers represent a major class of antihypertensive compounds. Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system. Oral candesartan 8–32 mg once daily is recommended for the treatment of adult patients with hypertension. Clinical trials have demonstrated that candesartan cilexetil is an effective agent in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal failure, retinopathy, and migraine in different populations of adult patients including patients with coexisting type 2 diabetes, metabolic syndrome, or kidney impairment. Clinical evidence confirmed that candesartan cilexetil provides better antihypertensive efficacy than losartan and is at least as effective as telmisartan and valsartan. Candesartan cilexetil, one of the current market leaders in BP treatment, is a highly selective compound with high potency, a long duration of action, and a tolerability profile similar to placebo. The most important and recent data from clinical trials regarding candesartan cilexetil will be reviewed in this article. |
format | Online Article Text |
id | pubmed-3253768 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2011 |
publisher | Dove Medical Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-32537682012-01-12 Differential clinical profile of candesartan compared to other angiotensin receptor blockers Cernes, Relu Mashavi, Margarita Zimlichman, Reuven Vasc Health Risk Manag Review The advantages of blood pressure (BP) control on the risks of heart failure and stroke are well established. The renin-angiotensin system plays an important role in volume homeostasis and BP regulation and is a target for several groups of antihypertensive drugs. Angiotensin II receptor blockers represent a major class of antihypertensive compounds. Candesartan cilexetil is an angiotensin II type 1 (AT[1]) receptor antagonist (angiotensin receptor blocker [ARB]) that inhibits the actions of angiotensin II on the renin-angiotensin-aldosterone system. Oral candesartan 8–32 mg once daily is recommended for the treatment of adult patients with hypertension. Clinical trials have demonstrated that candesartan cilexetil is an effective agent in reducing the risk of cardiovascular mortality, stroke, heart failure, arterial stiffness, renal failure, retinopathy, and migraine in different populations of adult patients including patients with coexisting type 2 diabetes, metabolic syndrome, or kidney impairment. Clinical evidence confirmed that candesartan cilexetil provides better antihypertensive efficacy than losartan and is at least as effective as telmisartan and valsartan. Candesartan cilexetil, one of the current market leaders in BP treatment, is a highly selective compound with high potency, a long duration of action, and a tolerability profile similar to placebo. The most important and recent data from clinical trials regarding candesartan cilexetil will be reviewed in this article. Dove Medical Press 2011 2011-12-12 /pmc/articles/PMC3253768/ /pubmed/22241949 http://dx.doi.org/10.2147/VHRM.S22591 Text en © 2011 Cernes et al, publisher and licensee Dove Medical Press Ltd. This is an Open Access article which permits unrestricted noncommercial use, provided the original work is properly cited. |
spellingShingle | Review Cernes, Relu Mashavi, Margarita Zimlichman, Reuven Differential clinical profile of candesartan compared to other angiotensin receptor blockers |
title | Differential clinical profile of candesartan compared to other angiotensin receptor blockers |
title_full | Differential clinical profile of candesartan compared to other angiotensin receptor blockers |
title_fullStr | Differential clinical profile of candesartan compared to other angiotensin receptor blockers |
title_full_unstemmed | Differential clinical profile of candesartan compared to other angiotensin receptor blockers |
title_short | Differential clinical profile of candesartan compared to other angiotensin receptor blockers |
title_sort | differential clinical profile of candesartan compared to other angiotensin receptor blockers |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3253768/ https://www.ncbi.nlm.nih.gov/pubmed/22241949 http://dx.doi.org/10.2147/VHRM.S22591 |
work_keys_str_mv | AT cernesrelu differentialclinicalprofileofcandesartancomparedtootherangiotensinreceptorblockers AT mashavimargarita differentialclinicalprofileofcandesartancomparedtootherangiotensinreceptorblockers AT zimlichmanreuven differentialclinicalprofileofcandesartancomparedtootherangiotensinreceptorblockers |